Aspirin related platelet reactivity as a determinant of ten year survival in high risk non-ST segment elevation myocardial infarction (NSTEMI) patients

Aspirin forms a cornerstone of management in patients with established cardiovascular disease (CVD). Despite proven efficacy, variability of aspirin response has long been recognised, with early studies suggesting rates of high on treatment platelet reactivity (HTPR) as ranging between 5 and 45%. Whether aspirin responsiveness relates to long-term prognosis in patients with CVD is unknown.

Source: Thrombosis Research - September 9, 2020 Category: Hematology Authors: Nazish Khan, Mamas A. Mamas, Alexandra Moss, Diana A. Gorog, Peter Nightingale, Angel Armesilla, Andrew Smallwood, Shahzad Munir, Saib Khogali, Ben Wrigley, James M. Cotton Tags: Letter to the Editors-in-Chief Source Type: research